Papers by Hagop M. Kantarjian
Page 2 · newest first
- Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched studyBlood Cancer Journal · 2025
- Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challengesCancer · 2025
- Chronic Myeloid LeukemiaJAMA · 2025
- A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemiaCancer · 2025
- Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemiaCancer · 2025
- Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesAmerican Journal of Hematology · 2025
- TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationBlood Advances · 2025
- Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacyLeukemia & lymphoma/Leukemia and lymphoma · 2025
- Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic LeukemiaClinical Lymphoma Myeloma & Leukemia · 2025
- Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic LeukemiaAmerican Journal of Hematology · 2025
- Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic DesignationAmerican Journal of Hematology · 2024
- Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsHaematologica · 2024
- Acute myeloid leukemia management and research in 2025CA A Cancer Journal for Clinicians · 2024
- Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapyBlood Advances · 2024
- Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettesLeukemia & lymphoma/Leukemia and lymphoma · 2024
- Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaCancer · 2024
- Venetoclax-Based Combination Regimens in Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
- Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabBlood Cancer Journal · 2024
- Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic MastocytosisBlood · 2024
- Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 AlterationsBlood · 2024
- Current status and research directions in acute myeloid leukemiaSHILAP Revista de lepidopterología · 2024
- Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies2024
- Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies2024
- Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international communityLeukemia · 2024
- Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicinBlood Cancer Journal · 2024
- Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directionsCancer · 2024
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2024
- Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLJournal of Clinical Oncology · 2024
- Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaAmerican Journal of Hematology · 2024
- Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisJCO Oncology Practice · 2024
- NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageCancer · 2024
- Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimensLeukemia & lymphoma/Leukemia and lymphoma · 2024
- FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.Journal of Clinical Oncology · 2024
- A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Journal of Clinical Oncology · 2024
- Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.Journal of Clinical Oncology · 2024
- A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.Journal of Clinical Oncology · 2024
- Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).Journal of Clinical Oncology · 2024
- Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.Journal of Clinical Oncology · 2024
- In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.Journal of Clinical Oncology · 2024
- A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.Journal of Clinical Oncology · 2024
- Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.Journal of Clinical Oncology · 2024
- A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).Journal of Clinical Oncology · 2024
- Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.Journal of Clinical Oncology · 2024
- Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.Journal of Clinical Oncology · 2024
- Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.Journal of Clinical Oncology · 2024
- Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationCancer · 2024
- Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure SyndromesNEJM Evidence · 2024
- Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseCancer · 2024
- Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaCell Reports Medicine · 2024
- Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2024